Vor Bio Appoints RA Capital’s Andrew Levin, M.D., Ph.D., and Forbion’s Wouter Joustra to Board of Directors
Vor Biopharma Inc. (VOR)
Company Research
Source: GlobeNewswire
BOSTON, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Vor Biopharma Inc. (Nasdaq: VOR), a clinical-stage biotechnology company dedicated to transforming the treatment of autoimmune diseases, today announced the appointment of Andrew Levin, M.D., Ph.D., Partner at RA Capital Management, and Wouter Joustra, General Partner at Forbion, to its Board of Directors. Their appointments follow the Company’s recently announced $150M PIPE financing, which included participation from both investors. “Andrew and Wouter bring highly complementary experience in life sciences investment, financing strategy, and board-level oversight. We are delighted to welcome them to our Board at an important moment for the Company,” said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of Vor Bio. “Their perspectives will be invaluable as we advance our global Phase 3 programs and position the Company to drive long-term shareholder value.” Dr. Levin is a Partner on the investment team at RA Capital Manag
Show less
Read more
Impact Snapshot
Event Time:
VOR
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VOR alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VOR alerts
High impacting Vor Biopharma Inc. news events
Weekly update
A roundup of the hottest topics
VOR
News
- Vor Biopharma (NASDAQ:VOR) had its price target lowered by analysts at JPMorgan Chase & Co. from $43.00 to $40.00. They now have an "overweight" rating on the stock.MarketBeat
- Vor Biopharma (NASDAQ:VOR) is now covered by analysts at TD Cowen. They set a "buy" rating on the stock.MarketBeat
- Vor Bio Announces $150 Million Private PlacementGlobeNewswire
- Vor Biopharma (VOR): Valuation Check After Positive Telitacicept Phase 3 Data and Upbeat JPMorgan Coverage [Yahoo! Finance]Yahoo! Finance
- Vor Biopharma (NASDAQ:VOR) is now covered by analysts at JPMorgan Chase & Co.. They set an "overweight" rating and a $43.00 price target on the stock.MarketBeat
VOR
Earnings
- 11/13/25 - Miss
VOR
Sec Filings
- 12/23/25 - Form SCHEDULE
- 12/19/25 - Form 4
- 12/19/25 - Form 4
- VOR's page on the SEC website